You don't need to be signed in to read BMJ Blogs, but you can register here to receive updates about other BMJ products and services via our site.

HCV/HIV co-infection

HIV/hepatitis C co-infection increases risk of hepatic decompensation

22 Apr, 14 | by Leslie Goode, Blogmaster

A recent study (Lo Re & Vincent (L&J)) presents disquieting findings regarding the relative risk of severe liver complications in HIV/Hepatitis C co-infected patients.

Hepatitis C (HCV) has received particular attention in STIs recently on account of its strong association with HIV sero-positivity in MSM (Yaphe & Klein (STIs)) and because of its growing incidence in some MSM populations (Giraudon & Barton (STIs)).  As for the outcomes of HCV in co-infected patients, there have been studies suggesting the benefit of ART in slowing progression of liver complications; but, L&J claim, theirs is the first to have established a significant difference in the outcomes of HIV co-infected patients.

L&J is a retrospective cohort study involving the records of 10,359 patients receiving care between 1997 and 2010 through the US Veterans Health Administration.  It establishes a relatively higher risk of hepatic decompensation for HCV co-infected, as opposed to HCV mono-infected patients:  HR 1.83 or HR 1.56 (depending on whether death is treated as a “competing risk”).  Cumulative incidence of decompensation at ten years for co-infected and mono-infected was, respectively, 7.4% and 4.8%.

The study also gives an indication of the impact of levels of ART success (in terms of maintenance of HIV RNA levels) on rates of hepatic decompensation in co-infected patients.  Co-infected patients who maintained HIV RNA levels at less than 1000 copies/mL had lower rates of hepatic decompensation than patients who did not, but these rates were still considerably higher than for mono-infected patients: HR 1.44.  Cumulative incidence of decompensation at ten years for co-infected with HIV RNA ≥ 1000 copies/mL was 7.6%.

In addition, the study examined various characteristics associated with higher levels of decompensation in co-infected patients – most interestingly, perhaps CD4 count at the study baseline.  Cumulative incidence of decompensation at ten years for co-infected patients with CD4 <200×106 was 8.1%, as against 6.9% for co-infected with CD4 ≥200×106.

The authors conclude that the considerably greater risk of decompensation in co-infected patients is only somewhat alleviated by effective ART.  They point out that their findings strongly support current guidelines for the earliest possible initiation of ART in co-infected patients, regardless of CD4 count, and may prompt earlier consideration of initiation of HCV to reduce the risk of liver complications

Sexually Transmitted Infections blog

Sexually Transmitted Infections

Discussion and suggestion space for readers of STIs.
Visit site

Creative Comms logo

Latest from Sexually Transmitted Infections

Latest from Sexually Transmitted Infections